Cargando…

S5-KL-1 CURRENT TREATMENT FOR DLBCL AND PROPHYLAXIS AND TREATMENT FOR SECONDARY CNS LYMPHOMA

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, comprising 30% of all lymphoma cases. More than 60% of patients can be cured with current standard treatment, R-CHOP. On the other hand, prognosis of patients with relapsed or refractory DLBCL is disappointing with less th...

Descripción completa

Detalles Bibliográficos
Autor principal:	Izutsu, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213082/ http://dx.doi.org/10.1093/noajnl/vdz039.016

Ejemplares similares

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes
por: Lim, Taekyu, et al.
Publicado: (2011)

S5-KL-1 CANCER GENOMIC MEDICINE: FROM BENCH TO CLINIC
por: Aburatani, Hiroyuki
Publicado: (2019)

NQPC-21 QOL EVALUATION IN THE TREATMENT COURSE OF CNS LYMPHOMA
por: Yamagishi, Yuki, et al.
Publicado: (2022)

SL3 PRIMARY CNS LYMPHOMA: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES
por: Grommes, Christian
Publicado: (2019)

SS1-KL-1 APPLICATION OF AI TECHNOLOGIES FOR MEDICAL CARE
por: Hamamoto, Ryuji
Publicado: (2019)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

CNS Involvement of DLBCL Presenting with an Unusual Non-Enhancing Infiltrative Mass
por: Hsueh, Fu-Sheng, et al.
Publicado: (2023)

The $Kl _{3}$ puzzle and current algebra
por: Banerjee, H
Publicado: (1970)

S4-KL-1 UPDATE OF WHO2016 CLASSIFICATION OF ADULT DIFFUSE GLIOMAS
por: Komori, Takashi
Publicado: (2019)

Leptomeningeal relapse in primary cutaneous DLBCL: Implications for a prophylactic CNS therapy
por: Sundriyal, Deepak, et al.
Publicado: (2020)

IL-4 CHALLENGES FOR MANAGEMENT OF PRIMARY CNS LYMPHOMA
por: Nagane, Motoo
Publicado: (2022)

Intravascular Lymphoma in the CNS: Options for Treatment
por: Nizamutdinov, Damir, et al.
Publicado: (2017)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
por: Nydegger, Anna, et al.
Publicado: (2021)

An audit on the diagnosis of primary CNS lymphoma
por: Joe, Dorothy, et al.
Publicado: (2021)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
por: Griffiths, Robert, et al.
Publicado: (2010)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies
por: Holdhoff, Matthias, et al.
Publicado: (2020)

Current and Emerging Pharmacotherapies for Primary CNS Lymphoma
por: Prodduturi, Prathima, et al.
Publicado: (2012)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
por: Shumilov, Evgenii, et al.
Publicado: (2023)

Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers
por: Jurczak, Wojciech, et al.
Publicado: (2015)

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
por: Harrysson, Sara, et al.
Publicado: (2021)

Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era
por: Jelicic, Jelena, et al.
Publicado: (2023)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

AS1-KL-1 DEVELOPMENT OF HIGH-DOSE CHEMOTHERAPY INCLUDING THIOTEPA COMBINED WITH AUTOLOGOUS PERIPHERAL BLOOD STEM CELL RESCUE
por: Hara, Junichi
Publicado: (2019)

ML-4 A case of primary CNS lymphoma diagnosed 5 years after stereotactic radiosurgery
por: Tabei, Yusuke, et al.
Publicado: (2021)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

Vitreoretinal lymphoma, secondary to non-CNS systemic lymphoma, masquerading as an infectious retinitis
por: Reddy, Varun, et al.
Publicado: (2019)

Systemic Drug Prophylaxis and Treatment of Sympathetic Ophthalmitis
Publicado: (1911)

Influence of corticosteroid treatment on CXCR4 expression in DLBCL
por: Martin, Sebastian, et al.
Publicado: (2023)

278. CNS Blastomycosis: A Descriptive Analysis and Review of Diagnosis and Treatment
por: Majdick, Kathryn, et al.
Publicado: (2019)

Keynote Lectures (KL)
Publicado: (2017)

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
por: Regier, Dean A., et al.
Publicado: (2022)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)

P1122: A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA
por: Habringer, Stefan, et al.
Publicado: (2023)

The Prophylaxis and Treatment of Typhoid Fever by the Anti-Typhoid Vaccine
Publicado: (1914)

Secondary prophylaxis in rheumatic fever: is it time to change?
por: Taddio, Andrea, et al.
Publicado: (2015)

Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia
por: Nakagawa, Noriharu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_435heuob7qhhlr936bk0leev87